Skip to content
2000
image of Bioanalytical Method for Simultaneous Quantification of Itraconazole and Atorvastatin in Human Plasma

Abstract

Introduction

Drug-drug interactions between statins and azole antifungal agents, due to the inhibition of the CYP3A4 enzyme by antifungals, increase the risk of adverse effects from statins. Thus, a precise bioanalytical method for quantifying Itraconazole and Atorvastatin in human plasma is essential.

Materials and Methods

A liquid chromatographic method with protein precipitation and liquid-liquid extraction was developed. Rosuvastatin calcium served as the internal standard. The method was validated per ICH M10 and USFDA guidelines and used to analyze spiked plasma samples.

Results

The method effectively separated Itraconazole, Atorvastatin, and the internal standard without plasma interference. It achieved linear responses for each drug in the 0.1-3.0 μg/mL range with regression coefficients > 0.99. The RSD for within-run and between-run responses was < 5%, and the average recovery exceeded 64%.

Discussion

The method accurately and precisely measured each analyte at the LLOQ level (0.1 μg/mL). A sensitive and selective bioanalytical HPLC method was developed, validated, and applied for the simultaneous estimation of Itraconazole and Atorvastatin in human plasma.

Conclusion

This method ensures safe and effective co-administration of these medications in clinical practice, benefiting patient care.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/dmb/10.2174/0118723128401590250922065135
2025-10-10
2026-01-05

  • From This Site

    /content/journals/dmb/10.2174/0118723128401590250922065135
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Nováková L. Challenges in the development of bioanalytical liquid chromatography–mass spectrometry method with emphasis on fast analysis. J. Chromatogr. A 2013 1292 25 37 10.1016/j.chroma.2012.08.087 22999195
    [Google Scholar]
  2. Ingle R.G. Zeng S. Jiang H. Fang W.J. Current developments of bioanalytical sample preparation techniques in pharmaceuticals. J. Pharm. Anal. 2022 12 4 517 529 10.1016/j.jpha.2022.03.001 36105159
    [Google Scholar]
  3. Alves G. Fortuna A. Falcão A. Bioanalysis in drug discovery and development: focus on pharmacokinetic studies. Biomed. Chromatogr. 2010 1 1 28
    [Google Scholar]
  4. Yuan Z. Yu X. Wu S. Wu X. Wang Q. Cheng W. Hu W. Kang C. Yang W. Li Y. Zhou X.Y. Instability mechanism of osimertinib in plasma and a solving strategy in the pharmacokinetics study. Front. Pharmacol. 2022 13 928983 10.3389/fphar.2022.928983 35935836
    [Google Scholar]
  5. Tripathi K.D. Essentials of Medical Pharmacology. Jaypee Brothers Medical Publishers 2008 10.5005/jp/books/10282
    [Google Scholar]
  6. Itraconazole: Uses, Interactions, Mechanism of Action. 2024 Available from: https://go.drugbank.com/drugs/DB01167
  7. Lestner J. Hope W.W. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin. Drug Metab. Toxicol. 2013 9 7 911 926 10.1517/17425255.2013.794785 23641752
    [Google Scholar]
  8. Itraconazole 2024 Available from: https: //pubchem.ncbi.nlm.nih.gov/substance/341141291
  9. Piérard G.E. Arrese J.E. Piérard-Franchimont C. Itraconazole. Expert Opin. Pharmacother. 2000 1 2 287 304 10.1517/14656566.1.2.287 11249550
    [Google Scholar]
  10. De Beule K. Van Gestel J. Pharmacology of Itraconazole. Drugs 2001 61 27 37 10.2165/00003495‑200161001‑00003 11219548
    [Google Scholar]
  11. Peng C.C. Shi W. Lutz J.D. Kunze K.L. Liu J.O. Nelson W.L. Isoherranen N. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug Metab. Dispos. 2012 40 3 426 435 10.1124/dmd.111.042739 22106171
    [Google Scholar]
  12. Atorvastatin: Uses, Interactions, Mechanism of Action. Available from: https://go.drugbank.com/drugs/DB01076
  13. ATORVASTATIN CALCIUM Available from: https://pubchem.ncbi.nlm.nih.gov/substance/252402708
  14. Neuvonen P. Niemi M. Backman J. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin. Pharmacol. Ther. 2006 80 6 565 581 10.1016/j.clpt.2006.09.003 17178259
    [Google Scholar]
  15. Taylor F. Huffman M.D. Macedo A.F. Moore T.H.M. Burke M. Davey Smith G. Ward K. Ebrahim S. Gay H.C. Statins for the primary prevention of cardiovascular disease. Cochrane Libr. 2013 2021 9 CD004816 10.1002/14651858.CD004816.pub5 23440795
    [Google Scholar]
  16. Elsby R. Hilgendorf C. Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin. Pharmacol. Ther. 2012 92 5 584 598 10.1038/clpt.2012.163 23047648
    [Google Scholar]
  17. Chauvin B. Drouot S. Barrail-Tran A. Taburet A.M. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin. Pharmacokinet. 2013 52 10 815 831 10.1007/s40262‑013‑0075‑4 23703578
    [Google Scholar]
  18. Moghadasian M.H. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Life Sci. 1999 65 13 1329 1337 10.1016/S0024‑3205(99)00199‑X 10503952
    [Google Scholar]
  19. Yang B.R. Seong J.M. Choi N.K. Shin J.Y. Lee J. Kim Y.J. Kim M.S. Park S. Song H.J. Park B.J. Co-medication of statins with contraindicated drugs. PLoS One 2015 10 5 e0125180 10.1371/journal.pone.0125180 25932626
    [Google Scholar]
  20. Kantola T. Kivistö K.T. Neuvonen P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 1998 64 1 58 65 10.1016/S0009‑9236(98)90023‑6 9695720
    [Google Scholar]
  21. Isohanni M.H. Neuvonen P.J. Palkama V.J. Olkkola K.T. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur. J. Clin. Pharmacol. 1998 54 7 561 565 10.1007/s002280050513 9832299
    [Google Scholar]
  22. Kaltenbach G. Levêque D. Peter J.D. Salmon J. Elkhaili H. Cavalier A. Salmon Y. Monteil H. Jehl F. Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. Antimicrob. Agents Chemother. 1996 40 9 2043 2046 10.1128/AAC.40.9.2043 8878578
    [Google Scholar]
  23. Jalava K.M. Olkkola K.T. Neuvonen P.J. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur. J. Clin. Pharmacol. 1996 51 3-4 331 334 10.1007/s002280050207 9010708
    [Google Scholar]
  24. Mazzu A. Lasseter K.C. Shamblen E.C. Agarwal V. Lettieri J. Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin. Pharmacol. Ther. 2000 68 4 391 400 10.1067/mcp.2000.110537 11061579
    [Google Scholar]
  25. Dybro AM Damkier P Rasmussen TB Hellfritzsch M Statin-associated rhabdomyolysis triggered by drug–drug interaction with itraconazole. Case Report 2016 2016 216457 10.1136/bcr‑2016‑216457
    [Google Scholar]
  26. Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J. Cardiol. 2004 94 9 1140 1146 10.1016/j.amjcard.2004.07.080 15518608
    [Google Scholar]
  27. Cox S.K. Orosz S. Burnette J. Frazier D. Microassay for determination of itraconazole and hydroxyitraconazole in plasma and tissue biopsies. J. Chromatogr., Biomed. Appl. 1997 702 1-2 175 180 10.1016/S0378‑4347(97)00378‑2 9449569
    [Google Scholar]
  28. Yao M. Chen L. Srinivas N.R. Quantitation of itraconazole in rat heparinized plasma by liquid chromatography–mass spectrometry. J. Chromatogr., Biomed. Appl. 2001 752 1 9 16 10.1016/S0378‑4347(00)00505‑3 11254202
    [Google Scholar]
  29. Sharma R.N. Pancholi S.S. HPLC-DAD method for the pharmacokinetic interaction study of atorvastatin with pioglitazone and cholestyramine in wistar rats. Sci. Pharm. 2014 82 3 555 570 10.3797/scipharm.1401‑18 25853068
    [Google Scholar]
  30. Carrier A. Parent J. Liquid chromatographic–mass spectrometric determination of itraconazole and its major metabolite, hydroxyitraconazole, in dog plasma. J. Chromatogr., Biomed. Appl. 2000 745 2 413 420 10.1016/S0378‑4347(00)00309‑1 11043759
    [Google Scholar]
  31. Karan Wadhwa Rana, A.C. Development and validation of HPLC-UV based bioanalytical method for the quantification of atorvastatin in rat plasma. World Journal of Advanced Research and Reviews 2020 7 3 121 132 10.30574/wjarr.2020.7.3.0327
    [Google Scholar]
  32. Porwal P.K. Talele G.S. Development of validated bioanalytical HPLC-UV method for simultaneous estimation of amlodipine and atorvastatin in rat plasma. Indian J. Pharm. Sci. 2015 77 6 742 750 10.4103/0250‑474X.174969 26997703
    [Google Scholar]
  33. Silva J. Basso J. Sousa J. Fortuna A. Vitorino C. Development and full validation of an HPLC methodology to quantify atorvastatin and curcumin after their intranasal co‐delivery to mice. Biomed. Chromatogr. 2019 33 10 e4621 10.1002/bmc.4621 31215044
    [Google Scholar]
  34. Jia J. Lu C. Liu G. Zhang M. Liu Y. Wang W. Weng L. Li S. Yu C. Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by liquid chromatography–isotope dilution tandem mass spectrometry method. Biomed Chromatogr 2010 24 6 648 654 10.1002/bmc.1341 19813178
    [Google Scholar]
  35. Verweij-van Wissen C.P.W.G.M. Burger D.M. Verweij P.E. Aarnoutse R.E. Brüggemann R.J.M. Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012 887-888 79 84 10.1016/j.jchromb.2012.01.015 22336695
    [Google Scholar]
  36. Imoto Y. Mino Y. Naito T. Ono T. Kawakami J. Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application. J. Pharm. Health Care Sci. 2020 6 1 11 10.1186/s40780‑020‑00167‑7 32391164
    [Google Scholar]
  37. Bharathi D.V. Hotha K.K. Sagar P.V.V. Kumar S.S. Reddy P.R. Naidu A. Mullangi R. Development and validation of a highly sensitive and robust LC–MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: Application to a bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008 868 1-2 70 76 10.1016/j.jchromb.2008.04.029 18485840
    [Google Scholar]
  38. Gubbins P.O. Gurley B.J. Bowman J. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J. Pharm. Biomed. Anal. 1998 16 6 1005 1012 10.1016/S0731‑7085(97)00062‑9 9547703
    [Google Scholar]
  39. Kousoulos C. Tsatsou G. Apostolou C. Dotsikas Y. Loukas Y.L. Development of a high-throughput method for the determination of itraconazole and its hydroxy metabolite in human plasma, employing automated liquid–liquid extraction based on 96-well format plates and LC/MS/MS. Anal. Bioanal. Chem. 2006 384 1 199 207 10.1007/s00216‑005‑0159‑6 16333603
    [Google Scholar]
  40. Redmann S. Charles B.G. A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy‐itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis. Biomed. Chromatogr. 2006 20 4 343 348 10.1002/bmc.569 16161186
    [Google Scholar]
  41. Koks C.H.W. Sparidans R.W. Lucassen G. Crommentuyn K.M.L. Beijnen J.H. Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. J Chromatogr B Analyt Technol Biomed Life. Sci 2002 767 1 103 110 10.1016/S0378‑4347(01)00550‑3 11865826
    [Google Scholar]
  42. Courlet P. Spaggiari D. Desfontaine V. Cavassini M. Alves Saldanha S. Buclin T. Marzolini C. Csajka C. Decosterd L.A. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2019 1125 121733 10.1016/j.jchromb.2019.121733 31374423
    [Google Scholar]
  43. Yacoub M. awwad, A.A.; Alawi, M.; Arafat, T. Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LCMS/MS. J. Chromatogr B Analyt Technol Biomed Life. Sci. 2013 917-918 36 47 10.1016/j.jchromb.2013.01.001 23369879
    [Google Scholar]
  44. Varghese S.J. Kochupappy Ravi T. Liquid chromatography/mass spectrometry method for the simultaneous determination of atorvastatin and telmisartan in human plasma. Anal. Chem. Lett. 2019 9 4 552 563 10.1080/22297928.2019.1649188
    [Google Scholar]
  45. El-Bagary R.I. Elkady E.F. El-Sherif Z.A. Kadry A.M. LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma. J. Chromatogr. Sci. 2014 52 8 773 780 10.1093/chromsci/bmt109 23885041
    [Google Scholar]
  46. Porwal P.K. Talele G.S. Development of validated HPLC-UV method for simultaneous determination of Metformin, Amlodipine, Glibenclamide and Atorvastatin in human plasma and application to protein binding studies. Bull. Fac. Pharm. Cairo Univ. 2017 55 1 129 139 10.1016/j.bfopcu.2016.10.002
    [Google Scholar]
  47. Rukthong P. Sangvanich P. Kitchaiya S. Jantratid E. Sathirakul K. The quantitation of atorvastatin in human plasma by solid phase micro-extraction followed by LC-MS/MS and its application to pharmacokinetics study. Songklanakarin J. Sci. Technol. 2013 2 35
    [Google Scholar]
  48. Croitoru O. Spiridon A.M. Belu I. Turcu-Ştiolică A. Neamţu J. Development and validation of an HPLC method for simultaneous quantification of clopidogrel bisulfate, its carboxylic acid metabolite, and atorvastatin in human plasma: application to a pharmacokinetic study. J. Anal. Methods Chem. 2015 2015 1 12 10.1155/2015/892470 26839733
    [Google Scholar]
  49. Zhou Y. Li J. He X. Jia M. Liu M. Li H. Xiong Z. Fan Y. Li W. Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its metabolites ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma and its application in a bioequivalence study. J. Pharm. Biomed. Anal. 2013 83 101 107 10.1016/j.jpba.2013.04.021 23711572
    [Google Scholar]
/content/journals/dmb/10.2174/0118723128401590250922065135
Loading
Bioanalytical Method for Simultaneous Quantification of Itraconazole and Atorvastatin in Human Plasma
Bentham Science Publishers ; https://doi.org/10.2174/0118723128401590250922065135
/content/journals/dmb/10.2174/0118723128401590250922065135
/content/journals/dmb/10.2174/0118723128401590250922065135
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: atorvastatin calcium ; UFLC ; itraconazole ; LLE ; Bioanalytical method ; rosuvastatin calcium
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test